Literature DB >> 31799060

Simplified approach to least-square fitting of fluorescence lifetime ophthalmoscopy (FLIO) data by fixating lifetimes.

Rowena Schultz1, Franziska Schuster1, Thomas Lehmann2, Johanna Schmidt1, Regine Augsten1, Martin Hammer1,3.   

Abstract

Fluorescence lifetime imaging ophthalmoscopy (FLIO) is a new imaging modality in ophthalmology. For clinical investigations, the amplitude-weighted mean of two or three lifetime components is usually analyzed. In this study, we investigated the effects of fixation of lifetime components. This resulted in slightly higher fit errors but mean lifetimes were highly correlated to those from fits with variable individual lifetimes. Furthermore, this approach resulted in a similarly good discrimination of diabetic retinopathy patients from controls, a reduction of the computational workload, a de-noising of the mean lifetime images and allows higher local resolution. Thus, fixation of lifetimes in the fit of FLIO data could be superior for clinical routine analysis of FLIO data.
© 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement.

Entities:  

Year:  2019        PMID: 31799060      PMCID: PMC6865094          DOI: 10.1364/BOE.10.005996

Source DB:  PubMed          Journal:  Biomed Opt Express        ISSN: 2156-7085            Impact factor:   3.732


  27 in total

1.  Monitoring macular pigment changes in macular holes using fluorescence lifetime imaging ophthalmoscopy.

Authors:  Lydia Sauer; Sven Peters; Johanna Schmidt; Dietrich Schweitzer; Matthias Klemm; Lisa Ramm; Regine Augsten; Martin Hammer
Journal:  Acta Ophthalmol       Date:  2016-10-24       Impact factor: 3.761

Review 2.  Review of clinical approaches in fluorescence lifetime imaging ophthalmoscopy.

Authors:  Lydia Sauer; Karl M Andersen; Chantal Dysli; Martin S Zinkernagel; Paul S Bernstein; Martin Hammer
Journal:  J Biomed Opt       Date:  2018-09       Impact factor: 3.170

3.  Multimodal nonlinear optical imaging of unstained retinas in the epi-direction with a sub-40 fs Yb-fiber laser.

Authors:  Gabrielle A Murashova; Christopher A Mancuso; Jacob L Canfield; Sanae Sakami; Krzysztof Palczewski; Grazyna Palczewska; Marcos Dantus
Journal:  Biomed Opt Express       Date:  2017-10-26       Impact factor: 3.732

4.  Retinal fluorescence lifetime imaging ophthalmoscopy measures depend on the severity of Alzheimer's disease.

Authors:  Susanne Jentsch; Dietrich Schweitzer; Kai-Uwe Schmidtke; Sven Peters; Jens Dawczynski; Karl-Jürgen Bär; Martin Hammer
Journal:  Acta Ophthalmol       Date:  2014-12-07       Impact factor: 3.761

5.  Fluorescence Lifetime Imaging in Stargardt Disease: Potential Marker for Disease Progression.

Authors:  Chantal Dysli; Sebastian Wolf; Katja Hatz; Martin S Zinkernagel
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-03       Impact factor: 4.799

6.  Fluorescence lifetime imaging of the ocular fundus in mice.

Authors:  Chantal Dysli; Muriel Dysli; Volker Enzmann; Sebastian Wolf; Martin S Zinkernagel
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-09-23       Impact factor: 4.799

7.  Fluorophores of the human retinal pigment epithelium: separation and spectral characterization.

Authors:  G E Eldred; M L Katz
Journal:  Exp Eye Res       Date:  1988-07       Impact factor: 3.467

8.  Fundus autofluorescence lifetimes are increased in non-proliferative diabetic retinopathy.

Authors:  Johanna Schmidt; Sven Peters; Lydia Sauer; Dietrich Schweitzer; Matthias Klemm; Regine Augsten; Nicolle Müller; Martin Hammer
Journal:  Acta Ophthalmol       Date:  2016-08-13       Impact factor: 3.761

9.  Fluorescence Lifetime Imaging Ophthalmoscopy: A Novel Way to Assess Macular Telangiectasia Type 2.

Authors:  Lydia Sauer; Rebekah H Gensure; Martin Hammer; Paul S Bernstein
Journal:  Ophthalmol Retina       Date:  2017-12-08

10.  Patterns of Fundus Autofluorescence Lifetimes In Eyes of Individuals With Nonexudative Age-Related Macular Degeneration.

Authors:  Lydia Sauer; Rebekah H Gensure; Karl M Andersen; Lukas Kreilkamp; Gregory S Hageman; Martin Hammer; Paul S Bernstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-03-20       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.